Enterocloster lavalensis

(aka Clostridium lavalense)

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Enterocloster lavalensis, (aka Clostridium lavalense), is a Gram-positive, spore-forming, strictly anaerobic, motile, rod-shaped bacterium. It has been detected in at least 5 gut microbiome compilation studies or metastudies. The DNA G+C content is 51–52%. Enterocloster lavalensis is probably a common, although minor, coloniser of the gut. (Domingo2009)



  • This organism has been recovered from human faeces (Alkhalil2017). Pathogenicity status unknown, or very unlikely to be pathogenic. Is a known gut commensal.
    • QUIRKS
  • In 68% of Europeans (unseenbio.com). Minor coloniser.
    • GENERAL CHARACTERISTICS (Domingo2009);
    Character Response
  • Substrates hydrolysed or digested:
  • meat;
  • ±
  • Strain-dependent hydrolysis or digestion:
  • milk;
  • 🌡
  • Temperature tolerance:
  • grows at 37℃; doesn't grow at 60℃; Grows optimally at 37℃.
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; galactose; glucose; mannose; lactose; maltose; sucrose; trehalose; salicin;
  • Active enzymes:
  • β-galactosidase;
    • SPECIAL FEATURES (Domingo2009);
    Character Response
  • ✓
  • Metabolites produced:
  • acetate (major); lactate (minor); succinate (minor); H₂; indole;
  • ✗
  • Haemolysis:
  • absent
  • Nitrate:
  • reduction is variable
    • RESPONSE TO ANTIBIOTICS (Goldstein2014); (Domingo2009);
    Class Active Resistant
  • Macrolides:
  • fidaxomicin;
  • Aminoglycosides:
  • kanamycin;
  • Heterocycles:
  • metronidazole;
  • Vancomycins:
  • teicoplanin;
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin;
  • colistin;

  • Domingo, M.-C., Huletsky, A., Boissinot, M., Hélie, M.-C., Bernal, A., Bernard, K. A., Grayson, M. L., Picard, F. J., & Bergeron, M. G. (2009). Clostridium lavalense sp. nov., a glycopeptide-resistant species isolated from human faeces. International Journal of Systematic and Evolutionary Microbiology, 59(Pt 3), 498–503.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Firmicutes Class:  Clostridia Order:  Eubacteriales Family:  Clostridiaceae Genus:  Enterocloster Alt. name:  Clostridium lavalense Gram stain:  + O2 Relation.:  strictly anaerobic Spore:  Endospore Motility:  Swimming Morphology:  Rod
    Health:  Unknown
    Source:  human faeces (Alkhalil2017)
    DNA G+C(%):  51–52
    Opt. T:  37℃
    Mid T(℃):  37(+)
    High T(℃):  60(neg)
    		Aesculin:  neg Urea:  neg Gelatin:  neg Starch:  neg Milk:  d Meat:  +
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    D-Arabinose:  w Fructose:  + Galactose:  + Glucose:  + Mannose:  + Rhamnose:  neg Ribose:  w L-Xylose:  w Cellubiose:  vr Lactose:  + Maltose:  + Melezitose:  neg Melibiose:  vr Sucrose:  + Trehalose:  + Amygdalin:  neg Glycogen:  neg Inulin:  neg Starch:  neg Adonitol:  neg Erythritol:  neg Glycerol:  neg Inositol:  neg Mannitol:  neg Sorbitol:  w Salicin:  +
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  + α-Glucosidase:  neg β-Glucuronidase:  neg Lecithinase:  neg Lipase:  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Acetate:  Major(+) Lactate:  minor(+) Succinate:  minor(+) H2:  + Indole:  +
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    kanamycin:  S(1000; disc)
    fidaxomicin:  S(0.06)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    teicoplanin:  S(<1.5)
    vancomycin:  R(>256)
    metronidazole:  S(<0.064)
    clindamycin:  Sens
    colistin:  R(10; disc)

    References

    SPECIFIC REFERENCES FOR ENTEROCLOSTER LAVALENSIS
  • Haas2020 - Reclassification of the Clostridium clostridioforme and Clostridium sphenoides clades as Enterocloster gen. nov. and Lacrimispora gen. nov., including reclassification of 15 taxa.
  • Huang2019 - Analysis of microbiota in elderly patients with Acute Cerebral Infarction
  • Takahashi2016 - Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease
  • Goldstein2014 - Comparative in vitro activities of SMT19969, a new antimicrobial agent, against 162 strains from 35 less frequently recovered intestinal Clostridium species: implications for Clostridium difficile recurrence.
  • Domingo2009 - Clostridium lavalense sp. nov., a glycopeptide-resistant species isolated from human faeces.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR ENTEROCLOSTER LAVALENSIS
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Yang2020 - Species-Level Analysis of Human Gut Microbiota With Metataxonomics.
  • Yang2020a - Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families
  • Zou2019 - 1,520 reference genomes from cultivated human gut bacteria enable functional microbiome analyses.
  • ...............................
    • GENERAL REFERENCES FOR ENTEROCLOSTER LAVALENSIS
  • Ludwig2009 - Revised road map to the phylum Firmicutes.
  • CCUG - Culture Collection University of Gothenburg - Entire Collection
  • Alkhalil2017 - Bacterial involvements in ulcerative colitis: molecular and microbiological studies
    • Added: April 08, 2021